Pharmaust Limited (AU:NUZ)
ASX:NUZ
Top Page
Pharmaust Limited
(Sydney:NUZ)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$0.08
â–Ľ(-23.00% Downside)
Action:ReiteratedDate:03/17/26
The score is primarily constrained by very weak financial performance (zero revenue, widening losses, accelerating cash burn, and rapid equity erosion). Technicals add further pressure due to a clear downtrend, while valuation is neutral-to-weak given the negative P/E and lack of dividend data.
Positive Factors
Debt-free balance sheet
Having zero reported debt materially reduces near-term refinancing and interest-cost risk, preserving operational flexibility. For a cash-burning developer, low leverage makes any necessary fundraising less encumbered by debt covenants and lowers fixed obligations over the next 2–6 months.
Negative Factors
Revenue fell to zero
A collapse to zero revenue signals loss of commercial momentum and undermines any near-term prospect of organic funding from sales. Without product sales, the company must rely on external financing or major partnerships, increasing execution and dilution risk over the coming months.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Having zero reported debt materially reduces near-term refinancing and interest-cost risk, preserving operational flexibility. For a cash-burning developer, low leverage makes any necessary fundraising less encumbered by debt covenants and lowers fixed obligations over the next 2–6 months.
Read all positive factors
Pharmaust Limited (NUZ) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$56.65M
Dividend YieldN/A
Average Volume (3M)1.10M
Price to Earnings (P/E)―
Beta (1Y)1.26
Revenue GrowthN/A
EPS GrowthN/A
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.01
Shares Outstanding708,128,660
10 Day Avg. Volume1,596,000
30 Day Avg. Volume1,096,098
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)25.24
Price to Sales (P/S)0.00
P/FCF Ratio-4.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.28Price Target Upside180.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Pharmaust Limited Business Overview & Revenue Model
Company Description
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate i...
How the Company Makes Money
null...
Pharmaust Limited Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
34
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 857.35K | 0.00 | 0.00 | 2.82M | 3.38M | 3.38M |
| Gross Profit | 855.71K | 0.00 | -1.64K | -929.53K | -223.52K | 3.07M |
| EBITDA | -9.45M | -18.48M | -9.45M | -9.45M | -1.30M | -1.30M |
| Net Income | -7.69M | -16.59M | -9.03M | -9.03M | -1.71M | -1.71M |
Balance Sheet | ||||||
| Total Assets | 11.12M | 4.36M | 11.12M | 6.13M | 6.13M | 10.08M |
| Cash, Cash Equivalents and Short-Term Investments | 9.72M | 4.18M | 9.72M | 2.71M | 2.71M | 3.02M |
| Total Debt | 0.00 | 0.00 | 0.00 | 1.05M | 1.05M | 1.28M |
| Total Liabilities | 896.61K | 1.54M | 896.61K | 2.24M | 2.23M | 2.23M |
| Stockholders Equity | 10.23M | 2.82M | 10.23M | 3.89M | 7.84M | 8.88M |
Cash Flow | ||||||
| Free Cash Flow | -5.17M | -14.29M | -5.17M | -1.60M | -1.38M | -1.08M |
| Operating Cash Flow | -5.17M | -14.29M | -5.17M | -1.56M | -1.33M | -937.97K |
| Investing Cash Flow | -1.17M | -21.55K | -1.17M | -34.93K | -43.38K | -138.04K |
| Financing Cash Flow | 13.34M | 8.76M | 13.34M | 1.89M | 770.99K | 1.22M |
Pharmaust Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | AU$56.65M | -4.29 | -254.33% | ― | ― | ― | |
42 Neutral | AU$55.73M | -5.28 | -62.49% | ― | ― | 10.78% | |
42 Neutral | AU$84.50M | -14.80 | -40.65% | ― | 700.00% | 26.88% | |
41 Neutral | AU$137.36M | -2.84 | 279.21% | ― | ― | 0.66% |
* Healthcare Sector Average
AU:NUZ
Pharmaust Limited
0.08
-0.05
-37.01%
LVCLF
Living Cell Technologies
―
―
―
PRNAF
Alterity Therapeutics
0.01
0.00
0.00%
AU:PTX
Prescient Therapeutics Limited
0.05
<0.01
12.77%
AU:RCE
Recce Pharmaceuticals Ltd.
0.48
0.12
33.43%
AU:ALA
Arovella Therapeutics Limited
0.07
>-0.01
-12.50%
Pharmaust Limited Corporate Events
Neurizon Sets April 2026 Expiry for NUZOA Listed Options
Mar 19, 2026
Neurizon Therapeutics has notified holders of its NUZOA listed options that these securities, each exercisable at $0.15 for one fully paid ordinary share, will expire at 5:00pm AEST on 30 April 2026. Official quotation of NUZOA on the ASX will cea...
Neurizon to Present NUZ-001 Science in HEALEY ALS Platform Trial Webinar
Mar 19, 2026
Neurizon Therapeutics will participate in a community webinar hosted by the Healey AMG Center for ALS, titled “HEALEY ALS Platform Trial Regimen I Science with Neurizon,” held on 19 March 2026 ET. The session will provide a high-level...
Neurizon Issues Director Shares, Affirms Compliance and Transparency
Mar 19, 2026
Neurizon Therapeutics has issued 9.5 million fully paid ordinary shares to its directors at $0.08 per share as part of their participation in the company’s December 2025 placement, a move previously approved by shareholders at a February 202...
Neurizon Therapeutics Seeks ASX Quotation for 9.5 Million New Shares
Mar 19, 2026
Neurizon Therapeutics Limited has applied for quotation on the ASX of 9,500,000 new ordinary fully paid shares under the code NUZ, with an issue date of 19 March 2026. The application, lodged as an Appendix 2A, progresses the formal listing of the...
Neurizon CEO Michael Thurn Resigns as Biotech Launches Global Search for Successor
Mar 15, 2026
Neurizon Therapeutics has announced that Managing Director and Chief Executive Officer Dr Michael Thurn has resigned and will step down from his executive duties on 16 March 2026, remaining through his notice period until July to support an orderl...
Neurizon Expands NUZ-001 Huntington’s Disease Data at ASENT 2026
Mar 4, 2026
Neurizon Therapeutics has presented new preclinical data on its lead candidate NUZ-001 at the ASENT 2026 meeting, strengthening mechanistic support for its use in Huntington’s disease models. The data show that both NUZ-001 and its active me...
Neurizon Therapeutics Options Lapse, Trimming Potential Equity Overhang
Mar 3, 2026
Neurizon Therapeutics Limited has informed the market that 682,500 options with an exercise price of $0.10, expiring on 28 February 2026, have lapsed unexercised. The expiry of these options marginally reduces the company’s pool of potential...
Neurizon Draws First $5m Tranche to Advance ALS Drug Trial
Feb 27, 2026
Neurizon Therapeutics has drawn down the first $5 million tranche of its previously announced $20 million strategic convertible note facility with Obsidian Global GP, providing immediate funding support for its clinical programs. The financing und...
Neurizon Taps A$5m in Convertible Note Funding From Obsidian
Feb 27, 2026
Neurizon Therapeutics has issued a cleansing notice ahead of the expected issuance of 3,575,500 unquoted convertible notes to New York-based Obsidian Global GP under a two-year, up to A$20 million funding facility. The first A$5 million drawdown w...
Neurizon issues 10m shares under convertible note, affirms compliance and disclosure
Feb 27, 2026
Neurizon Therapeutics has issued 10,000,000 fully paid ordinary shares to Obsidian Global GP, LLC under a previously approved convertible note facility, following shareholder approval at a recent general meeting. The company confirmed the shares w...
Neurizon Begins Pivotal NUZ-001 Dosing in HEALEY ALS Platform Trial
Feb 25, 2026
Neurizon Therapeutics has begun dosing the first participant with its lead candidate NUZ-001 in Regimen I of the HEALEY ALS Platform Trial, a multicentre adaptive Phase 2/3 study run by the Sean M. Healey AMG Center for ALS at Mass General Brigha...
Neurizon Narrows Half-Year Loss as Other Income Jumps and Net Assets Strengthen
Feb 25, 2026
Neurizon Therapeutics Limited reported a sharply lower half-year loss for the period ended 31 December 2025, with the deficit narrowing 23.9% to $5.54 million as other income surged 241.5% to nearly $6.0 million. The company’s balance sheet ...
Neurizon Publishes General Meeting Results and Enhances Investor Engagement
Feb 20, 2026
Neurizon Therapeutics Limited has released the results of its general meeting, disclosing details of the resolutions considered and proxy votes received, as required under Australian corporate and listing rules. The company also directed investors...
Neurizon Therapeutics Issues Heavily Qualified General Meeting Presentation
Feb 20, 2026
Neurizon Therapeutics has released a general meeting presentation outlining information for shareholders while stressing that the material should not be regarded as financial, legal, tax or investment advice. The company emphasises that the presen...
Neurizon Therapeutics Director Marcus Hughes Increases Shareholding
Feb 3, 2026
Neurizon Therapeutics director Marcus Hughes has increased his equity stake in the company through the on-market purchase of 750,000 fully paid ordinary shares at $0.08 per share, for a total consideration of $60,000. Following the transaction, Hu...
Neurizon Secures FDA Green Light and Full Funding for Late-Stage NUZ-001 ALS Trial
Jan 30, 2026
Neurizon reported a pivotal quarter marked by the US FDA lifting the clinical hold on NUZ-001’s IND and subsequently clearing the drug to enter the HEALEY ALS Platform Trial as Regimen I, positioning the asset at the centre of global ALS dru...
Neurizon Secures A$6m R&D Tax Rebate to Fund HEALEY ALS Trial
Jan 29, 2026
Neurizon Therapeutics has secured a A$6.0 million cash rebate under the Australian Government’s RD Tax Incentive program for FY2025, reflecting a 48.5% rebate on eligible domestic and overseas RD activities, supported by an Advance Overseas...
Neurizon Therapeutics Seeks ASX Quotation for 73.5 Million New Shares
Jan 29, 2026
Neurizon Therapeutics Limited has applied for quotation on the ASX of 73,508,717 new ordinary fully paid shares under the code NUZ, with an issue date of 29 January 2026, following previously announced transactions. The substantial new share issua...
Neurizon Raises $5.9m in Entitlement Offer to Advance ALS Trial
Jan 27, 2026
Neurizon Therapeutics has raised approximately $5.88 million through a well-supported pro-rata non-renounceable entitlement offer, issuing around 73.5 million new shares at $0.08 each, including strong oversubscription demand from eligible shareho...
Neurizon Therapeutics Updates Market on Director Michael Thurn’s Revised Securities Holdings
Jan 22, 2026
Neurizon Therapeutics has reported a change in the holdings of director Dr Michael Thurn, who maintains both direct and indirect interests in the company through family accounts and personal holdings of shares, options and performance rights. The ...
Neurizon Calls Virtual-Only General Meeting as It Shifts to Digital Shareholder Communications
Jan 20, 2026
Neurizon Therapeutics Limited has called a virtual-only General Meeting of shareholders for 20 February 2026 at 2:00pm AEDT, to be held via an online meeting platform, with all meeting materials, including the Notice of Meeting and explanatory sta...
Neurizon Locks In Global Trademark Protection for NEURIZON Brand Across Key Pharma Markets
Jan 19, 2026
Neurizon Therapeutics has secured registered trademark protection for the NEURIZON brand across its key global commercial markets, including the United States, European Union, United Kingdom, Australia and Japan, covering pharmaceutical research a...
Neurizon Sets Out 2026 Execution Plan Ahead of HEALEY ALS Trial Enrolment
Jan 15, 2026
Neurizon Therapeutics has released an investor webinar presentation outlining recent strategic and operational progress, including a strengthened funding position, regulatory developments and preparations to commence patient enrolment in the HEALE...
Neurizon to Host Investor Webinar on Funding and HEALEY ALS Trial Milestones
Jan 7, 2026
Neurizon Therapeutics has scheduled a shareholder webinar for 15 January 2026 to brief investors on the execution of recent funding initiatives, regulatory developments and upcoming operational milestones related to its participation in the HEALEY...
Neurizon Therapeutics Options Lapse, Trimming Potential Future Dilution
Jan 6, 2026
Neurizon Therapeutics Limited has reported the expiry of 3 million unlisted options exercisable at $0.15 that were due to lapse on 31 December 2025, with none of these options being exercised before their expiry. The cessation of these securities ...
Neurizon Opens A$17.1m Entitlement Offer to Fund Neurodegenerative Pipeline
Jan 4, 2026
Neurizon Therapeutics has opened a pro-rata non-renounceable entitlement offer to raise up to approximately A$17.1 million before costs, giving eligible shareholders the right to subscribe for two new shares for every five held at an offer price o...
Neurizon Clears Secondary Trading for $6.3m Share Placement
Jan 1, 2026
Neurizon Therapeutics has issued 79,330,864 fully paid ordinary shares at $0.08 per share to sophisticated and professional investors under a placement first announced in late December 2025. The company has confirmed the shares were issued without...
Neurizon Maps Regulatory Pathway as NUZ-001 Advances in HEALEY ALS Trial
Jan 1, 2026
Neurizon Therapeutics has provided a regulatory update on NUZ-001, its investigational ALS therapy, confirming that the US FDA has declined its initial Fast Track Designation request but offered detailed feedback on the additional clinical data ne...
Neurizon Director Increases Stake Through Participation in Share Placement
Jan 1, 2026
Neurizon Therapeutics has disclosed a change in director Sergio Duchini’s interests, with Duchini, through Kelbury Pty Ltd, acquiring 416,667 fully paid ordinary shares at $0.12 per share in a recent placement. Following the transaction, his...
Neurizon Therapeutics Seeks ASX Quotation for 79.3 Million New Shares
Dec 31, 2025
Neurizon Therapeutics Limited has applied to the ASX for quotation of 79,330,864 new ordinary fully paid shares, to be issued on 2 January 2026 under code NUZ. The application, lodged as an Appendix 2A, indicates a significant expansion of the com...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.